Evidence map›Paper›PMID 30827930›Full record

ArticleEBioMedicine2019

Integrated epigenomic profiling reveals endogenous retrovirus reactivation in renal cell carcinoma.

Kyle T Siebenthall, Chris P Miller, Jeff D Vierstra, Julie Mathieu, Maria Tretiakova, Alex Reynolds, Richard Sandstrom, Eric Rynes, Eric Haugen, Audra Johnson and 11 more

Open access · goldAbstract read
In one paragraph

Article in EBioMedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 39 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Current perspective on the impact of endogenous retroviruses in clear cell renal cell carcinoma.Kidney cancer journal : official journal of the Kidney Cancer Association · 2023
    Article
  9. Article
  10. Review
  11. From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. The Zebrafish Model to Understand Epigenetics in Renal Diseases.International journal of molecular sciences · 2021
    Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 3 institutions in 1 country.

Kyle T SiebenthallAltius Institute for Biomedical Sciences, Seattle, WA 98121, United States.
Chris P MillerDepartment of Pathology, University of Washington, Seattle, WA 98195, United States.
Jeff D VierstraAltius Institute for Biomedical Sciences, Seattle, WA 98121, United States.
Julie MathieuInstitute for Stem Cell and Regenerative Medicine, Seattle, WA 98109, United States; Department of Comparative Medicine, University of Washington, Seattle, WA 98195, United States.
Maria TretiakovaDepartment of Pathology, University of Washington, Seattle, WA 98195, United States.
Alex ReynoldsAltius Institute for Biomedical Sciences, Seattle, WA 98121, United States.
Richard SandstromAltius Institute for Biomedical Sciences, Seattle, WA 98121, United States.
Eric RynesAltius Institute for Biomedical Sciences, Seattle, WA 98121, United States.
Eric HaugenAltius Institute for Biomedical Sciences, Seattle, WA 98121, United States.
Audra JohnsonAltius Institute for Biomedical Sciences, Seattle, WA 98121, United States.
Jemma NelsonAltius Institute for Biomedical Sciences, Seattle, WA 98121, United States.
Daniel BatesAltius Institute for Biomedical Sciences, Seattle, WA 98121, United States.
Morgan DiegelAltius Institute for Biomedical Sciences, Seattle, WA 98121, United States.
Douglass DunnAltius Institute for Biomedical Sciences, Seattle, WA 98121, United States.
Mark FrerkerAltius Institute for Biomedical Sciences, Seattle, WA 98121, United States.
Michael BuckleyAltius Institute for Biomedical Sciences, Seattle, WA 98121, United States.
Rajinder KaulAltius Institute for Biomedical Sciences, Seattle, WA 98121, United States.
Ying ZhengDepartment of Bioengineering, University of Washington, Seattle, WA 98195, United States; Kidney Research Institute, Seattle, WA 98104, United States.
Jonathan HimmelfarbDivision of Nephrology, Department of Medicine, University of Washington, Seattle, WA 98195, United States; Kidney Research Institute, Seattle, WA 98104, United States.
Hannele Ruohola-BakerDepartment of Biochemistry, University of Washington, Seattle, WA 98195, United States; Institute for Stem Cell and Regenerative Medicine, Seattle, WA 98109, United States.
Shreeram AkileshDepartment of Pathology, University of Washington, Seattle, WA 98195, United States; Kidney Research Institute, Seattle, WA 98104, United States. Electronic address: shreeram@uw.edu.
Altius Institute for Biomedical Sciences · USUniversity of Washington · USCalifornia Institute for Regenerative Medicine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTranscriptional dysregulation drives cancer formation but the underlying mechanisms are still poorly understood. Renal cell carcinoma (RCC) is the most common malignant kidney tumor which canonically activates the hypoxia-inducible transcription factor (HIF) pathway. Despite intensive study, novel therapeutic strategies to target RCC have been difficult to develop. Since the RCC epigenome is relatively understudied, we sought to elucidate key mechanisms underpinning the tumor phenotype and its clinical behavior.

methodsWe performed genome-wide chromatin accessibility (DNase-seq) and transcriptome profiling (RNA-seq) on paired tumor/normal samples from 3 patients undergoing nephrectomy for removal of RCC. We incorporated publicly available data on HIF binding (ChIP-seq) in a RCC cell line. We performed integrated analyses of these high-resolution, genome-scale datasets together with larger transcriptomic data available through The Cancer Genome Atlas (TCGA).

findingsThough HIF transcription factors play a cardinal role in RCC oncogenesis, we found that numerous transcription factors with a RCC-selective expression pattern also demonstrated evidence of HIF binding near their gene body. Examination of chromatin accessibility profiles revealed that some of these transcription factors influenced the tumor's regulatory landscape, notably the stem cell transcription factor POU5F1 (OCT4). Elevated POU5F1 transcript levels were correlated with advanced tumor stage and poorer overall survival in RCC patients. Unexpectedly, we discovered a HIF-pathway-responsive promoter embedded within a endogenous retroviral long terminal repeat (LTR) element at the transcriptional start site of the PSOR1C3 long non-coding RNA gene upstream of POU5F1. RNA transcripts are induced from this promoter and read through PSOR1C3 into POU5F1 producing a novel POU5F1 transcript isoform. Rather than being unique to the POU5F1 locus, we found that HIF binds to several other transcriptionally active LTR elements genome-wide correlating with broad gene expression changes in RCC.

interpretationIntegrated transcriptomic and epigenomic analysis of matched tumor and normal tissues from even a small number of primary patient samples revealed remarkably convergent shared regulatory landscapes. Several transcription factors appear to act downstream of HIF including the potent stem cell transcription factor POU5F1. Dysregulated expression of POU5F1 is part of a larger pattern of gene expression changes in RCC that may be induced by HIF-dependent reactivation of dormant promoters embedded within endogenous retroviral LTRs.

Indexed as

EpigenomicsBasic Helix-Loop-Helix ProteinsBinding SitesCarcinoma, Renal CellCell Line, TumorCytochrome ReductasesEndogenous RetrovirusesEndothelial PAS Domain-Containing Protein 1Gene Expression Regulation, NeoplasticHumansHypoxia-Inducible Factor 1Kidney NeoplasmsOctamer Transcription Factor-3Oxidoreductases Acting on Sulfur Group DonorsPhosphoric Diester HydrolasesPromoter Regions, GeneticBasic Helix-Loop-Helix ProteinsCytochrome ReductasesEndothelial PAS Domain-Containing Protein 1ENPP3 protein, humanGFER protein, humanHypoxia-Inducible Factor 1Octamer Transcription Factor-3Oxidoreductases Acting on Sulfur Group DonorsPhosphoric Diester HydrolasesPOU5F1 protein, humanProteinsPSORS1C3 lncRNA, humanPyrophosphatasesRNA, Long NoncodingUBE2D2 protein, humanUbiquitin-Conjugating EnzymesCancer epigeneticsCancer stem cellKidney cancerRegulatory genomicsRenal cell carcinomaTranscription factors

Identifiers

PMID30827930
PMCPMC6441874
OpenAlexW2919977258

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.